Their pricings could indicate a coming resurgence according to Jordan Saxe, head of healthcare listings for the Nasdaq stock exchange. This weeks listings indicate that the appetite to invest in innovative healthcare companies is back and the pipeline of biotech companies looking to tap the public markets is continuing to grow Saxe said